Analysts Offer Insights on Healthcare Companies: Supernus Pharmaceuticals (SUPN) and Zynex Inc (OtherZYXI)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Supernus Pharmaceuticals (SUPN) and Zynex Inc (ZYXI) with bullish sentiments.

Supernus Pharmaceuticals (SUPN)

B.Riley FBR analyst David Buck reiterated a Buy rating on Supernus Pharmaceuticals yesterday and set a price target of $68. The company’s shares closed yesterday at $41.65.

Buck observed:

“We reiterate our Buy rating and $68 PT for Supernus (SUPN) shares. We highlight 3Q18 results which grew a strong 76% Y/Y to $0.52 topping our $0.44 and $0.43 consensus. Revenue growth of 28% to $103M topped our $101.6M forecast and consensus of $100.8M. Trokendi XR grew a strong 34% above our $78.9M forecast and $78.3M consensus while Oxtellar XR grew 9% to $20.4M. Supernus narrowed 2018 product sales guidance from $385M-$400M to $388M-$395M versus our in-print $397.4M and consensus of $391.2M. Supernus raised its operating profit guidance which includes the $15M one-time upfront payment for purchase of Biscayne Pharmaceuticals which closed in to $120M-$125M.”

According to TipRanks.com, Buck is a 4-star analyst with an average return of 9.5% and a 56.5% success rate. Buck covers the Healthcare sector, focusing on stocks such as Amneal Pharmaceuticals Inc, Corcept Therapeutics Inc, and Spectrum Pharmaceuticals.

Currently, the analyst consensus on Supernus Pharmaceuticals is a Strong Buy with an average price target of $57.60, implying a 38.3% upside from current levels. In a report issued on October 22, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $56 price target.

.

See today’s analyst top recommended stocks >>

Zynex Inc (ZYXI)

In a report released today, Marc Wiesenberger from B.Riley FBR maintained a Buy rating on Zynex Inc, with a price target of $7. The company’s shares closed yesterday at $3.44.

Wiesenberger said:

“Before market open on 11/6, Buy-rated Zynex (ZYXI, $7 PT) reported upside 3Q (Sep) results, marking its ninth consecutive quarter of positive net income. Numbers overall bested our and consensus estimates and were consistent with our thesis that ZYXI can achieve meaningful FCF. In this regard, the company generated $3.1M in FCF (up 14% Y/Y), and equating to a 1.2x cash conversion ratio in 3Q. New orders for the company’s high-margin NexWave device grew 30% Y/Y , and 10% sequentially, thanks primarily to an expanded and more efficient sales force.”

Wiesenberger has an average return of 8.5% when recommending Zynex Inc.

According to TipRanks.com, Wiesenberger is ranked #3201 out of 4907 analysts.

Zynex Inc has an analyst consensus of Moderate Buy, with a price target consensus of $7.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts